|Day Low/High||88.03 / 89.06|
|52 Wk Low/High||72.30 / 94.19|
Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.
Stocks fall sharply on Thursday after a hawkish set of minutes from last month's Federal Reserve meeting cements the case for near-term interest rate hikes.
The Swiss drugmaker will pay $2.1 billion for Endocyte, justifying the Nasdaq-listed biotech's pivot to prostate treatment last year.
It's time for the central bank to show the same level of concern for their misplaced aggression.
U.S. stock futures decline after a hawkish set of minutes from last month's Federal Reserve meeting; American Express, PayPal and Travelers report earnings; Facebook believes hack was done by spammers, says a report; Novartis to buy Endocyte for $2.1 billion.
Tesla will pay $20 million as part of the settlement with Elon Musk paying another $20 million.
The rating is based on an analysts' view that Wednesday's full legalization of cannabis in Canada will be a boon for the company.
- Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo
With 38 million Americans suffering from migraines, the FDA's approval of Eli Lilly's preventative migraine drug Emgality can help them get their lives back. We spoke with Christi Shaw, president, Lilly Bio-Medicines for all the details.
Let's check out the latest charts and indicators for some technical guidance.
Ajovy is the second anti-calcitonin gene-related peptide (CGRP) drug approved by the FDA to prevent migraines.
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Here are two I think will bounce back before the end of the year.
The pharmaceutical giant's American depository receipts jumped on the heels of a report that the company's chairman is mulling a breakup of the firm.
Drug pricing remains front and center as healthcare companies start reporting quarterly results.
The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.
These names are showing bullish or bearish reversal patterns over the past week.
- Galaxies of Hope offers a unique digital experience that engages users through the art of visual storytelling to connect with others to understand NET cancer - Using real-life stories and voices of patients, caregivers, and physicians in the NET...
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
Adamis' device to treat allergic reactions should compete effectively with Mylan's popular EpiPen, according to an analyst.
Stocks ended slightly higher Friday, after giving up most of the day's gains in the final minutes of trading.
The drugmaker may have made a low, but the charts indicate we are a long way from a bottom.
U.S. stock futures are rising Friday and global stocks rebound on strong gains in China; Deutsche Bank is higher even after receiving a fresh rebuke from the Fed over 'critical deficiencies' in its financial planning; Nike's sales in North America bounce back.
Happy Friday! These are the stories you must know ahead of the opening bell.
-- Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%)
A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.